Hereditary Sensory and Autonomic Neuropathy Type 2 Overview
Learn About Hereditary Sensory and Autonomic Neuropathy Type 2
- Hereditary sensory and autonomic neuropathy type 2
- Giaccai type acroosteolysis
- HSAN2
- Hereditary sensory neuropathy type 2
- Hereditary sensory radicular neuropathy, recessive form
- Morvan disease
- Neurogenic acroosteolysis
- Neuropathy, congenital sensory
- Neuropathy, progressive sensory, of children
Dysautonomia Center Llp
Horacio Kaufmann is a Neurologist in New York, New York. Dr. Kaufmann is rated as an Elite provider by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Familial Dysautonomia, Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, and Orthostatic Hypotension.
Thorsten Hornemann practices in Zurich, Switzerland. Mr. Hornemann is rated as an Elite expert by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Hereditary Sensory Neuropathy Type 1 (HSN1), Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, Anhidrosis, and Gastric Bypass.
Ingo Kurth practices in Aachen, Germany. Mr. Kurth is rated as an Elite expert by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Hajdu-Cheney Syndrome, Hereditary Sensory and Autonomic Neuropathy Type 2, Hereditary Sensory Neuropathy Type 1 (HSN1), Anhidrosis, and Bone Marrow Transplant.
Summary: This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
Summary: The study will collect clinical information from patients with FD and allow them to give blood to help develop biological markers of the disease to aid diagnosis and treatment. This is a non-invasive, non-interventional, observation study that poses only minimal risk for participants. The study will document the clinical features of patients with FD overtime by storing their routine clinical test ...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center